Yahoo · Nov 3, 2026
Pfizer Inc. Q3 2026 Earnings Call Summary
Moby summary of Pfizer Inc.'s Q3 2026 earnings call

NYSE · BHVN
Healthcare · Biotechnology
$15.61
Down-$0.37 (-2.37%)
Updated Nov 4, 2026, 10:12 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BHVN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
BHVN closed at $15.61 after 21 trading sessions, up 29.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $15.46 | $16.09 | $15.25 | $15.61 | 2.02M |
| Nov 2, 2026 | $15.98 | $16.105 | $15.08 | $15.16 | 2.59M |
| Oct 30, 2026 | $15.46 | $16.33 | $15.12 | $15.42 | 3.16M |
| Oct 29, 2026 | $15.46 | $16.49 | $15.46 | $16.49 | 2.45M |
| Oct 28, 2026 | $15.11 | $15.87 | $14.955 | $15.52 | 3.15M |
| Oct 27, 2026 | $14.44 | $15.30 | $14.13 | $15.29 | 2.43M |
| Oct 26, 2026 | $13.94 | $14.6973 | $13.695 | $14.45 | 2.68M |
| Oct 23, 2026 | $15.215 | $15.37 | $13.83 | $13.88 | 4.69M |
| Oct 22, 2026 | $16.10 | $16.54 | $14.45 | $14.69 | 30.51M |
| Oct 21, 2026 | $11.90 | $12.1647 | $11.625 | $11.75 | 1.44M |
| Oct 20, 2026 | $11.35 | $11.845 | $11.07 | $11.81 | 1.53M |
| Oct 19, 2026 | $11.01 | $11.52 | $10.865 | $11.35 | 1.69M |
| Oct 16, 2026 | $11.31 | $11.40 | $10.70 | $10.78 | 2.42M |
| Oct 15, 2026 | $10.95 | $11.66 | $10.94 | $11.43 | 1.45M |
| Oct 14, 2026 | $11.39 | $11.50 | $10.82 | $10.93 | 1.78M |
| Oct 13, 2026 | $11.79 | $11.79 | $11.16 | $11.42 | 2.43M |
| Oct 12, 2026 | $11.91 | $11.99 | $11.65 | $11.81 | 1.62M |
| Oct 9, 2026 | $11.90 | $12.27 | $11.745 | $12.08 | 1.37M |
| Oct 8, 2026 | $11.83 | $12.12 | $11.46 | $11.93 | 2.7M |
| Oct 7, 2026 | $11.86 | $12.2318 | $11.845 | $11.88 | 2.15M |
| Oct 6, 2026 | $13.00 | $13.04 | $11.88 | $12.08 | 3.05M |
The latest Smart Investors Daily articles mentioning BHVN.
Company
Market Activity
Research & News


BHVN research
Filterable reporting and market headlines.
Filters are reflected in the page URL for sharing and back-button support.
5 matching articles.
Yahoo · Nov 3, 2026
Moby summary of Pfizer Inc.'s Q3 2026 earnings call
Fintel · Nov 2, 2026
Benzinga · Oct 30, 2026
Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.
Yahoo · Oct 30, 2026
Biohaven (BHVN) reported a narrower quarterly net loss alongside new preclinical data on its BHV-1420 program in membranous nephropathy, giving investors two concrete updates to weigh on earnings and pipeline progress. Biohaven’s latest updates landed after a strong run, with a 1-day share price return of 6.25% and a 30-day share price return of 24.08% helping push the year to date share price return to 52.12%. This comes even as the 1-year total shareholder return declined 5.18% and the...
Yahoo · Oct 29, 2026
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today provided a review of recent accomplishments and anticipated upcoming developments for the third quarter ended September 30, 2026.
The latest Smart Investors Daily articles mentioning BHVN.